Background: This study was to investigate the prognostic significance of clinicopathologic characteristics in patients with clear-cell carcinoma (CCC) of the ovary.
introduction Clear-cell carcinoma (CCC) of the ovary represents 5%-10% of all epithelial ovarian cancers and is frequently characterized by chemoresistances and recurrences resulting in a poor prognosis [1] [2] [3] [4] . In the USA, the incidence of CCC of the ovary is <5% of all epithelial ovarian cancers, but the incidence of CCC of the ovary in Japan reported to be >20% of all epithelial ovarian cancers. The reason for this disparity is not well known [3, 4] .
Previous studies showed that CCC of the ovary tended to present at earlier stages, with 59%-71% of all patients presenting with stages I and II diseases [3] [4] [5] [6] [7] [8] . The fact that many CCC of the ovary were detected early has been explained by the slow-growing tumor behavior [9] and the frequent presentation of tumors as relatively large pelvic masses [1, 7] .
CCC is an aggressive subtype of ovarian cancer characterized by poor chemosensitivity, which leads it to be associated with a worse prognosis than the more common serous cell type cancers [3, 8] . Investigators have tried to determine prognostic factors that influence survival in CCC of the ovary. Histological cell type, stage, and residual tumor are known to be the factors influencing survival [3, 4, 10, 11] . However, histological grading in CCC of the ovary was accepted as useless for long time because most of the patients with CCC of the ovary showed poor survival, irrespective of histological grade [12] [13] [14] .
While paclitaxel-based combination chemotherapy results in an increased overall survival in patients with epithelial ovarian cancer, there are little data on the use of this chemotherapeutic original article regimen in patients with CCC of the ovary. The response rate of CCC of the ovary is known to be 11% with platinum-based chemotherapy and 22%-56% with paclitaxel-based combination chemotherapy [8, 11] . These indicate that paclitaxel-based chemotherapy regimens have a higher response rate compared with platinum-based chemotherapy regimens. However, a recent study showed that there was no difference in survival between patients treated with paclitaxel-based chemotherapy and patients treated with platinum-based combination chemotherapy in either early or advanced cases, indicating the need for further studies [4] . Recently, the Korean Gynecologic Oncology Group (KGOG) retrospectively studied the clinical characteristics of 201 cases of CCC of the ovary and found that the survival rate of patients with CCC of the ovary was more favorable than initially expected. Therefore, we obtained pathological slides from each institution for central review toward the goal of determining any pathological characteristics that may influence prognosis in CCC of the ovary.
In this study, we investigated the significance of the universal grading system on prognosis of CCC of the ovary. The clinical characteristics and response to chemotherapeutic regimens were also evaluated in patients with CCC of the ovary.
materials and methods patients
Two hundred and one cases of pathologically proven CCC of the ovary diagnosed from January 1995 to December 2003 were registered in the KGOG registry.
The following information was collected from the medical records and analyzed for clinical significances: age, International Federation of Gynecology and Obstetrics (FIGO) stage, initial CA 125 level, type of surgery, residual tumor size, type of adjuvant treatment, date of first disease progression or recurrence, and date of last contact or death.
For the central review, all pathological slides from the primary surgery were sent to the Korea Gynecologic Pathologic Study Group (KGPSG) and were reviewed thoroughly by 10 gynecologic pathologists with no knowledge of clinical information. Cell type and histological grade were determined by consensus of more than two-thirds of member's opinion. In cases of disagreement, the 10 pathologists voted for a final pathological decision on the basis of more than half the member's opinion.
On the base of central histological review, 51 cases were excluded. Reasons of exclusion are lack of pathological slides (45 cases), wrong histological cell type (three cases of serous adenocarcinoma), and improper medical records (three cases).
The cell types of all tumors were classified according to the World Health Organization (WHO) criteria, which define CCC of the ovary on the basis of the presence of typical clear or hobnail cells, but oxyphilic, cuboidal, and signet ring cell types were considered, as well.
For histological grading, the Silverberg [13] grading system was adopted, which is applicable for all histological types of epithelial ovarian cancer. In brief, architectural grade was scored as 1 point for a glandular pattern, 2 points for a papillary pattern, and 3 points for a solid pattern. Nuclear grade was also scored as follows: 1 point for mild nuclear pleomorphism, 2 points for moderate nuclear pleomorphism, and 3 points for greatest degree of atypia in at least one-half of a low power (·40) field. Strict criteria for the identification of mitotic figures were employed, and only nuclei with definite morphological features of metaphase, anaphase, or telophase were counted in the most mitotically active area in a tumor. Just hyperchromatic or apoptotic nuclei were excluded. A minimum of 20 fields was assessed, and the highest count of MFs/10 HPFs was scored as 1, 2, and 3 according to 0-9, 10-24, and > 25 MFs/10 HPFs, respectively.
A total score of 3-5 points was graded as grade 1, 6-7 points as grade 2, and 8-9 points as grade 3.
treatment
Most of the patients underwent comprehensive surgical staging procedures, including total hysterectomy, bilateral salpingo-oophorectomy, peritoneal washing cytology, infracolic omentectomy, and pelvic and/or paraaortic lymphadenectomy. In cases of stage I disease, pelvic and/or paraaortic lymphadenectomy depended on each surgeon's policy.
Postoperative adjuvant chemotherapy was carried out in every patient after initial surgery. Platinum-based combination chemotherapy was popular before 1998, but paclitaxel-based combination chemotherapy was the most common regimen after 1998, when the Ministry of Health and Welfare in Korea approved paclitaxel as a primary chemotherapy agent in epithelial ovarian cancers. Platinum-based combination chemotherapies consisted of cisplatin (75 mg/m with carboplatin (area under the curves 5-6) every 3 weeks for 6 cycles was the most common first-line chemotherapeutic regimen after 1998. Second look operation and secondary cytoreductive surgery were done on the basis of each surgeon's preference. In cases of persistent or recurrent disease, combination therapy with a topoisomerase I inhibitor and platinum was the most common second-line chemotherapeutic regimen. characteristics. The Kaplan-Meier method and log-rank test were used for determining survival distribution and differences in each group. The Cox regression model was used for univariate and multivariate analysis of prognostic factors with P value of <0.05 considered statistically significant. The forward stepwise likelihood ratio test was used to prevent the strong effect of one factor over the others and resultant obscuration of the significance of the other factors. A P value of <0.5 was considered statistically significant in the forward stepwise likelihood ratio.
results
The median age of 150 patients with CCC of the ovary was 46.8 years (range 26.3-79.8 years). Most of the patients were diagnosed at stage I (61.3%, 92 of 150 patients), followed in frequency by stage III (26%, 39 of 150 patients). Median tumor diameter was 10.4 cm, and mean initial CA 125 level was 70.8 U/ml. Optimal cytoreduction with residual tumor <1 cm was accomplished in 89% of patients. Paclitaxel-based and platinum-based combination chemotherapies were used in 61.7% and 38.3% of patients, respectively. Using Silverberg's universal grading system, there were 32% grade I, 52.7% grade II, and 15.3% grade III disease (Table 1) .
Patients with CCC of the ovary showed 103.6 months overall survival and 57% 5-year survival rate (Figure 1) . Stage, universal grade, initial CA 125 level, and residual tumor were significant prognostic factors on univariate analysis; however, stage was the only statistically significant factor on multivariate analysis (P < 0.001) (Table 2; Figure 2 ). Except for universal grade, the other histological prognostic factors such as cell type, histological pattern, and FIGO grade showed no statistical significance (Table 3) . On a forward stepwise likelihood ratio test, which can exclude any obscuring effect of an extremely dominant factor over others, universal grade and residual tumor showed statistical significance in prognosis of patients with CCC of the ovary (Table 4) .
Survival of patients with CCC of the ovary treated with paclitaxel-based combination chemotherapy was not significantly different compared with that of patients treated with platinum-based combination chemotherapy (Table 2) . discussion Different grading systems have been used at different institutions, at the expense of both interinstitutional and intrainstitutional variabilities [12] . Among popular grading systems, the FIGO grading system is on the basis of architectural features and the WHO grading system takes into account both architectural and nuclear features. The universal grading system proposed by Silverberg, which is on the basis of architectural features, nuclear pleomorphism, and mitotic counts, is considered to provide useful prognostic information and is applicable to all histological types of ovarian cancers [12, 14] . However, it has long been noted that CCC of the ovary cannot be graded by universal grading system because prognostic analysis did not achieve clinical significance [12] . However, our results showed that histological grade is one of the significant prognostic factors in patients with CCC of the ovary. The skepticism toward histological grading in determining prognosis for CCC of the ovary is not on the basis of the technical difficulty of the grading system, but the doubt of their clinical significance.
A study reported that the universal grade for 88 cases of CCC of the ovary did not show any statistical significance for survival on univariate or multivariate analysis [12] . However, our study showed that if we removed the strong effect of stage, then universal grade and optimal cytoreduction showed prognostic significance for the survival of patients with CCC of the ovary (Table 4 ). In our study, a forward stepwise likelihood ratio test was successful in preventing the overwhelming effect of stage on other factors. Furthermore, this study is the largest series to date of pathological reviews of CCC of the ovary using the universal grading system. Clinical characteristics of CCC of the ovary were investigated in some larger series; however, central pathological slide reviews larger than that accomplished in our study have not been carried out previously [8, 12] .
In this study, CCC of the ovary showed a more favorable prognosis than was expected, with 57% overall 5-year survival rate. In stage I disease, 5-year survival rate of CCC of the ovary is comparable to that of other epithelial ovarian cancers (82% versus 85%). However, advanced-stage CCC of the ovary showed extremely poorer prognosis than the other epithelial ovarian cancers (7% versus 25%), with the stage serving as the strongest prognostic factor ( Table 2) . As many investigators have already stated, the relatively large proportion of stage I disease explains why there are rather favorable overall survival rates associated with CCC of the ovary [1, 3, 4, 7, 8, 15, 16] .
Optimal cytoreduction also showed statistical significance on prognosis in patients with CCC of the ovary. Optimal cytoreduction is a well-known prognostic factor in other histological types of epithelial ovarian cancers, as well [3, 4, 8] . Our result confirmed again the significance of optimal cytoreduction, emphasizing the importance of an aggressive surgical approach in patients with CCC of the ovary.
Our result showed no statistical difference between paclitaxel-and platinum-based combination chemotherapy, demonstrating the need for further clinical trials to determine optimal chemotherapeutic regimens for patients with CCC of the ovary (Table 2) . Paclitaxel-based combination chemotherapy was reported to be effective in the treatment of CCC of the ovary in previous studies [8, 11, 17] . However, a recent study reported that there was no survival benefit 
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according to chemotherapeutic differences in the patients who received complete surgical staging procedures and conventional chemotherapy [4] . Our result showed again that there was no prognostic difference according to paclitaxel-or nonpaclitaxel-based chemotherapeutic regimens in CCC of the ovary. Though the commonality in the usage of paclitaxelbased combination chemotherapy was affected not by physician's decision but by the government's policy, further prospective randomized studies are needed to compare the effectiveness between paclitaxel-and platinum-based chemotherapy in CCC of the ovary. The optimal chemotherapeutic regimen is still being debated, illustrating the need for further clinical trials to identify effective new chemotherapeutic agents. Ongoing clinical trials to investigate the effectiveness of topoisomerase I inhibitors may provide clinical information toward determining the optimal chemotherapy regimen in patients with CCC of the ovary.
In conclusion, this study showed that the universal grading system is applicable to CCC of the ovary and provides useful information about prognosis. Aside from stage, the most prominent factor, histological grade and optimal cytoreduction were also determined to be significant prognostic factors in patients with CCC of the ovary. Paclitaxel-based combination chemotherapy was not effective in CCC of the ovary, demonstrating the need for further clinical trials toward identifying optimal chemotherapeutic regimens to be used in patients with CCC of the ovary.
